Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development. The company is headquartered in Cambridge, Massachusetts and currently employs 539 full-time employees. The company went IPO on 2013-07-24. The firm is focused on developing and delivering transformative therapies for patients living with rare diseases. The company markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for debilitating hemolytic anemia. Its lead product candidate in its portfolio, PYRUKYND (mitapivat), is an activator of both wild-type and mutant pyruvate kinase, or PK, enzymes for the potential treatment of hemolytic anemias. The company is also developing tebapivat, a novel PK activator, for the potential treatment of lower-risk myelodysplastic syndromes, or LR MDS, and hemolytic anemias; AG-181, its phenylalanine hydroxylase, or PAH, stabilizer for the potential treatment of phenylketonuria, or PKU; and AG-236, an siRNA in-licensed from Alnylam Pharmaceuticals, Inc., targeting the transmembrane serine protease 6, or TMPRSS6 gene for the potential treatment of polycythemia vera, or PV.
How did AGIO's recent EPS compare to expectations?
The most recent EPS for Agios Pharmaceuticals Inc is $, expectations of $.
How did Agios Pharmaceuticals Inc AGIO's revenue perform in the last quarter?
Agios Pharmaceuticals Inc revenue for the last quarter is $
What is the revenue estimate for Agios Pharmaceuticals Inc?
According to of Wall street analyst, the revenue estimate of Agios Pharmaceuticals Inc range from $ to $
What's the earning quality score for Agios Pharmaceuticals Inc?
Agios Pharmaceuticals Inc has a earning quality score of /. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does Agios Pharmaceuticals Inc report earnings?
Agios Pharmaceuticals Inc next earnings report is expected in
What are Agios Pharmaceuticals Inc's expected earnings?
Agios Pharmaceuticals Inc expected earnings is $, according to wall-street analysts.
Did Agios Pharmaceuticals Inc beat earnings expectations?
Agios Pharmaceuticals Inc recent earnings of $ expectations.
